Probiotics and Gut Microbiota Modulation in Inflammatory Disorders

Probiotics are defined as live microorganisms which, when administered in adequate amounts, confer health benefits upon the host. Their capacity to shape the composition and function of the gut microbiota has become central to strategies aimed at preventing or ameliorating inflammatory disorders. In conditions such as inflammatory bowel disease, irritable bowel syndrome and chronic diarrhoea, dysbiosis—or an imbalance in microbial communities—often coincides with compromised barrier integrity, aberrant immune signalling and altered metabolic outputs. Probiotic strains may restore equilibrium by competitive exclusion of pathogens, enhancement of mucosal barrier function, modulation of innate and adaptive immune responses and promotion of beneficial metabolites such as short-chain fatty acids. Advances in high-throughput sequencing and metabolomics have unveiled specific host–microbe interactions and enabled the design of targeted microbial therapies. These interventions offer global significance given the rising incidence of inflammatory diseases and their burden on healthcare systems. Emerging evidence emphasises the need for strain-specific selection, optimal dosing regimens and mechanistic understanding to translate microbiota modulation into routine clinical practice.

Research from Nature Portfolio

Recent clinical trials have investigated the efficacy of a novel Lactiplantibacillus plantarum strain in young adults with chronic diarrhoea. A double-blind, randomised placebo-controlled study over a 28-day intervention demonstrated a modest yet statistically significant reduction in symptom severity, underscoring the therapeutic potential of strain-specific probiotics in functional inflammatory disorders. Although limitations include a short follow-up period and absence of systemic biomarker analysis, the trial highlights the feasibility of large-scale probiotic interventions for symptom management.

Foundational work using a murine inflammation model has elucidated mechanisms by which a Lactobacillus rhamnosus strain restores impaired intestinal barrier function. The study revealed preservation of goblet cell populations, reinforcement of mucus layer integrity and transcriptional upregulation of genes related to epithelial motility and cytoprotection. Crucially, the protective effects were shown to depend upon adhesive pili structures, offering insight into microbe–host interactions that underpin barrier enhancement and anti-inflammatory responses.

Probiotics and Gut Microbiota Modulation in Inflammatory Disorders publication trend

The graph below shows the total number of articles in probiotics and gut microbiota modulation in inflammatory disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Probiotics: Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Gut microbiota: The community of microorganisms residing in the gastrointestinal tract, encompassing bacteria, archaea, viruses and fungi.

Dysbiosis: A disrupted or imbalanced microbiota composition associated with disease states.

Short-chain fatty acids (SCFAs): Metabolites such as acetate, propionate and butyrate produced by microbial fermentation of dietary fibres, with roles in barrier function and immune regulation.

Intestinal barrier: The physical and functional interface—including epithelial cells, mucus layer and tight junctions—that prevents translocation of harmful substances.

Immunomodulation: The process by which certain agents modify the immune response, either by enhancing or suppressing specific pathways.

References

1. Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial. Nature Communications (2024).
2. The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. Scientific Reports (2019).
3. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients (2023).
4. Bacteriocin-Producing Probiotic Lactic Acid Bacteria in Controlling Dysbiosis of the Gut Microbiota. Frontiers in Cellular and Infection Microbiology (2022).